Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427332 | 1.00 | DPP4 (0.45) | DPP4TSHRHSD17B10ALDH1A1MEN1 | |
| SCHEMBL2185042 | 0.88 | DPP4 (0.42) | DPP4TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL23535454 | 0.85 | TSHR (0.60) | TSHRHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL30427170 | 0.85 | TSHR (0.60) | TSHRHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL17150208 | 0.84 | DPP4 (0.47) | DPP4TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL2249995 | 0.84 | TSHR (0.46) | DPP4TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL3079030 | 0.84 | MEN1 (0.51) | TSHRMEN1KMT2ARAB9AHSP90AA1 | |
| SCHEMBL3079283 | 0.81 | JMJD6 (0.56) | TSHRALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL24746841 | 0.81 | ALDH1A1 (0.49) | DPP4TSHRHSD17B10ALDH1A1MEN1 | |
| SCHEMBL18341514 | 0.81 | NPC1 (0.46) | DPP4TSHRHSD17B10ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-118786117-A | Heterocyclic amides and methods of use thereof | 亚根达医疗公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4433457-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023092098-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-3426351-B1 | BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-09 | — | — | EP | disclosed |
| EP-3426351-B1 | BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LTD (AU) | 2020-12-09 | — | — | EP | disclosed |
| US-10787434-B2 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY, LTD (AU) | 2020-09-29 | — | — | US | disclosed |
| US-10787434-B2 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | CTXT PTY, LTD (AU) | 2020-09-29 | — | — | US | disclosed |
| EP-3426351-A1 | BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153520-A1 | BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153520-A1 | BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787434-B2 | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | HBB, HBG2, HBZ | DPP4 4600/4885TSHR 619/4885HSD17B10 2429/4885 |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | DPP4 4285/4885TSHR 3378/4885HSD17B10 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.